Aktuellt
SENASTE
Redeye comments on Sprint Bioscience announcing a rights issue. The capital raise aligns with our expectations but comes at a lower subscription price than we estimated earlier this year. We will adjust our estimates and valuation once the company communicates the rights issue’s outcome in mid-November.
LÄS MER
